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Introduction
Familial Mediterranean Fever (FMF) is the most com-
mon hereditary autoinflammatory syndrome affecting
>10,000 people in Israel. FMF is caused by mutations in
the MEFV gene, which encodes for the pyrin protein
that is part of the inflammation complex that activates
IL-1b. Evidence from case reports/series and one con-
trolled study supports IL-1 blockage as a potential treat-
ment for FMF. Canakinumab (CAN) is a selective fully
human monoclonal anti-IL-1b antibody.
Objectives
This study served as a proof of concept to evaluate the
role of CAN in the treatment of pediatric colchicine
resistant (CR)-FMF.
Methods
This was a 2-center open-label, single-arm study. The
population consisted of CR FMF patients (pts) 4-20
years of age, with a history of at least 3 documented
FMF attacks in the 3 months prior to enrollment.
Pts entered a 30-day run-in period (RI) during which
FMF attacks were documented in a diary. Pts who
experienced an investigator-confirmed FMF attack dur-
ing RI were eligible to enter the treatment phase and
receive a SC injection of CAN 2 mg/kg (max 150 mg)
every 4 weeks for three times with the 1st dose given
during an attack. The dose was doubled to 4 mg/kg
(max 300 mg) if an attack occurred between Day 1 and
Day 29 visits. Following the end of the treatment period,
pts were followed until Day 144 or until an attack
occurred, whichever occurred first. Primary outcome
was the proportion of pts with ≥50% reduction in FMF
attack rate during the treatment vs. pretreatment period.
Results
Fifteen Israeli pts (9 males, 6 females) with CR FMF
entered the RI period and 7 (median age 9.5 yrs.; 6.8-
14.9 yrs.), advanced to the treatment phase. In total, 6/7
(86%) pts had a ≥50% reduction in their FMF attack rate
during the treatment period vs. the pretreatment period.
The median attack rate was reduced by 89% from 2.7
per 28 days prior to CAN to 0.3 per 28 days during
treatment; 2 pts had their CAN dose up titrated. Ele-
vated median baseline CRP and SAA normalized by Day
8, ESR by Day 28 and all remained normal for remain-
der of trial. There was no evidence of neutralizing anti-
body formation. In all, 11 adverse events (AEs) in 4 pts
were reported after the first CAN dose; all were mild
except for 2 moderate AEs (Strep infection, laceration)
assessed as unrelated to study treatment by the study
investigator. No AEs led to medication discontinuation.
Conclusion
In this study of pediatric pts with colchicine resistant
FMF, canakinumab every 4 weeks substantially reduced
the FMF attack rate, consistent with similar findings in
adults. AEs were manageable. A larger study is needed
to better evaluate the benefit of canakinumab in FMF.
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